Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Celltrion Wins Bid to Supply Remsima®, Infliximab Biosimilar, and Herzuma®, Trastuzumab Biosimilar, in Peru

May 2, 2024

On 2 May 2024, Celltrion announced that it has won a 12 month tender to supply Remsima®, biosimilar to Janssen’s Remicade® (infliximab) and Herzuma®, biosimilar to Roche’s Herceptin® (trastuzumab), in Peru.  Celltrion expects to capture 86% of Peru’s infliximab market and 50% of Peru’s trastuzumab market.  Remicade® will be supplied from the end of May while Herzuma® will be supplied from July 2024.

This follows Celltrion’s recent tender successes regarding Remsima SC® in Denmark(April 2024), Norway (February 2024), and Sicily (January 2024).  In February 2024, Celltrion also secured a series of tenders in Peru to supply Herzuma® (trastuzumab biosimilar), Truxima® (rituximab biosimilar) and Yuflyma® (adalimumab biosimilar).   These contracts effectively secured more than 50% of the Peruvian rituximab and trastuzumab markets, and an estimated 20% of the Peruvian adalimumab market.